European Investment Bank VP Attends Signature Event at BiondVax Extending Financing Agreement With BiondVax to €24million

JERUSALEM, June 26, 2019 /PRNewswire/ -- The Board of Directors and Management of BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), was honored to host Mr. Ambroise Fayolle, Vice-President of the European Investment Bank (EIB), during his visit to BiondVax's new mid-size commercial scale manufacturing facility in Israel. During his visit, Mr. Fayolle, together with Dr. Ron Babecoff, BiondVax's President and CEO, signed the previously announced financing agreement extension through which the EIB has supported both construction of BiondVax's new facility and the ongoing pivotal, clinical efficacy, Phase 3 trial of M-001, BiondVax's universal flu vaccine candidate. 

Dr. Babecoff noted, "I am grateful for the EIB's innovative financing support of BiondVax's universal flu vaccine development.  The EIB's support has enabled us to conduct a large pivotal, clinical efficacy, Phase 3 trial in Europe, and construct a mid-size commercial scale manufacturing facility in Jerusalem. It is an honor to host Mr. Fayolle and his colleagues."

The transaction between EIB and BiondVax was initiated and is supported by kENUP Foundation.

BiondVax is currently conducting a pivotal, clinical efficacy, Phase 3 trial of M-001 in Europe. 4,094 participants were recruited prior to the 2018/19 flu season, and preparations are proceeding as planned towards the trial's second season of 2019/20, in which about 8,000 participants are expected to be enrolled. The placebo-controlled trial will assess safety and effectiveness of M-001 alone in reducing flu illness and severity in adults aged 50 years and older, with at least half aged 65 and older. Results are expected by the end of 2020.                       

In parallel, the NIAID/NIH is conducting a Phase 2 clinical trial of M-001 in the USA, with results anticipated by the end of 2019.

About BiondVax

BiondVax (NASDAQ: BVXV) is a Phase 3 clinical stage biopharmaceutical company developing a universal flu vaccine. The vaccine candidate, called M-001, is designed to provide multi-strain and multi-season protection against current and future, seasonal and pandemic influenza. BiondVax's proprietary technology utilizes a unique combination of conserved and common influenza virus peptides intended to stimulate both arms of the immune system for a cross-protecting and long-lasting effect. In a total of 6 completed Phase 1/2 and Phase 2 clinical trials, covering 698 participants, the vaccine has been shown to be safe, well-tolerated, and immunogenic. The ongoing pivotal Phase 3 clinical trial aims to assess safety and effectiveness of M-001 in reducing flu illness and severity. Please visit www.biondvax.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Litigation Reform Act of 1995. Words such as "expect," "believe," "intend," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements. These forward-looking statements reflect the management's current views with respect to certain current and future events and are subject to various risks, uncertainties and assumptions that could cause the results to differ materially from those expected by the management of BiondVax Pharmaceuticals Ltd. Risks and uncertainties include, but are not limited to, the prosecution and outcome of the ongoing Phase 2 and Phase 3 trials and any subsequent trials; timing of receipt of regulatory approval of the new manufacturing facility; ability to demonstrate the efficacy and safety of the vaccine; the timing of clinical trials and marketing approvals; the risk that drug development involves a lengthy and expensive process with uncertain outcome; the ability of the Company to maintain, preserve and defend its intellectual property and patents granted; whether our  vaccine candidate will successfully advance through the clinical trial process on a timely basis, or at all, and receive approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies; the adequacy of available cash resources and the ability to raise capital when needed. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in our Annual Report on Form 20-F for the year ended December 31, 2018 filed with the U.S. Securities and Exchange Commission, or SEC, which is available on the SEC's website, www.sec.gov, and in the Company's periodic filings with the SEC. We undertake no obligation to revise or update any forward-looking statement for any reason.

Contact Details

Joshua E. Phillipson | +972 8 930 2529 | [email protected]  

View original content to download multimedia:http://www.prnewswire.com/news-releases/european-investment-bank-vp-attends-signature-event-at-biondvax-extending-financing-agreement-with-biondvax-to-24million-300875446.html

SOURCE Biondvax Pharmaceuticals Ltd